595 related articles for article (PubMed ID: 32461371)
1. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
2. T cells discriminate between groups C1 and C2 HLA-C.
Sim MJW; Stotz Z; Lu J; Brennan P; Long EO; Sun PD
Elife; 2022 May; 11():. PubMed ID: 35587797
[TBL] [Abstract][Full Text] [Related]
3. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.
Wang QJ; Yu Z; Griffith K; Hanada K; Restifo NP; Yang JC
Cancer Immunol Res; 2016 Mar; 4(3):204-14. PubMed ID: 26701267
[TBL] [Abstract][Full Text] [Related]
4. Identification and affinity enhancement of T-cell receptor targeting a KRAS
Zhang M; Xu W; Luo L; Guan F; Wang X; Zhu P; Zhang J; Zhou X; Wang F; Ye S
Commun Biol; 2024 Apr; 7(1):512. PubMed ID: 38684865
[TBL] [Abstract][Full Text] [Related]
5. Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.
Dillard P; Casey N; Pollmann S; Vernhoff P; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Oncoimmunology; 2021; 10(1):1936757. PubMed ID: 34235003
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen.
Wu D; Gallagher DT; Gowthaman R; Pierce BG; Mariuzza RA
Nat Commun; 2020 Jun; 11(1):2908. PubMed ID: 32518267
[TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
8. Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.
Bai P; Zhou Q; Wei P; Bai H; Chan SK; Kappler JW; Marrack P; Yin L
Sci China Life Sci; 2021 Dec; 64(12):2144-2152. PubMed ID: 33740187
[TBL] [Abstract][Full Text] [Related]
9. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
Lu D; Chen Y; Jiang M; Wang J; Li Y; Ma K; Sun W; Zheng X; Qi J; Jin W; Chen Y; Chai Y; Zhang CWH; Liang H; Tan S; Gao GF
Nat Commun; 2023 Oct; 14(1):6389. PubMed ID: 37828002
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity.
Mariuzza RA; Wu D; Pierce BG
Front Immunol; 2023; 14():1303304. PubMed ID: 38045695
[TBL] [Abstract][Full Text] [Related]
11. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
[TBL] [Abstract][Full Text] [Related]
12. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic high affinity T cell receptor targeting a KRAS
Poole A; Karuppiah V; Hartt A; Haidar JN; Moureau S; Dobrzycki T; Hayes C; Rowley C; Dias J; Harper S; Barnbrook K; Hock M; Coles C; Yang W; Aleksic M; Lin AB; Robinson R; Dukes JD; Liddy N; Van der Kamp M; Plowman GD; Vuidepot A; Cole DK; Whale AD; Chillakuri C
Nat Commun; 2022 Sep; 13(1):5333. PubMed ID: 36088370
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.
Levin N; Kim SP; Marquardt CA; Vale NR; Yu Z; Sindiri S; Gartner JJ; Parkhurst M; Krishna S; Lowery FJ; Zacharakis N; Levy L; Prickett TD; Benzine T; Ray S; Masi RV; Gasmi B; Li Y; Islam R; Bera A; Goff SL; Robbins PF; Rosenberg SA
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38816232
[TBL] [Abstract][Full Text] [Related]
15. T cell receptors employ diverse strategies to target a p53 cancer neoantigen.
Wu D; Gowathaman R; Pierce BG; Mariuzza RA
J Biol Chem; 2022 Mar; 298(3):101684. PubMed ID: 35124005
[TBL] [Abstract][Full Text] [Related]
16. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.
Shen M; Chen S; Han X; Hao Y; Wang J; Li L; Chen T; Wang B; Zou L; Zhang T; Zhang W; Han X; Wang W; Yu H; Li K; Liu S; Jin A
Cancer Immunol Immunother; 2024 Jun; 73(8):150. PubMed ID: 38832948
[TBL] [Abstract][Full Text] [Related]
17. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.
Lu YC; Zheng Z; Robbins PF; Tran E; Prickett TD; Gartner JJ; Li YF; Ray S; Franco Z; Bliskovsky V; Fitzgerald PC; Rosenberg SA
Mol Ther; 2018 Feb; 26(2):379-389. PubMed ID: 29174843
[TBL] [Abstract][Full Text] [Related]
18. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
[TBL] [Abstract][Full Text] [Related]
19. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
20. Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells.
Wang S; Zhang X; Zou X; Wen M; Gan C; Jiang X; Li M; Shen R; Zhu D; Yao A; Fang Y; Fox BA; Hu HM; Yu G; Wang X
Cancer Immunol Immunother; 2023 May; 72(5):1301-1313. PubMed ID: 36436020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
